30 January 2024
RUA Life Sciences
Plc
("RUA Life Sciences", the
"Company" or the "Group")
Change of
Auditor
RUA Life Sciences plc (AIM:
RUA.L), the holding company of a group of medical device businesses
focused on the exploitation of Elast-Eon™, the world-leading
long-term implantable biostable polyurethane, announces that,
following a competitive audit tender process undertaken by the
Company, the Board has approved the appointment of RSM UK LLP
("RSM") as the Group's new external auditor. Grant Thornton UK LLP
("Grant Thornton") has resigned as the Group's auditor.
RSM will conduct the audit of the
Group's financial statements for the financial period to 31 March
2024, and a proposal to re-appoint RSM as auditors of the Group
will be subject to shareholders' approval at the 2024 Annual
General Meeting.
Grant Thornton has been the auditor
for the Company since 2006, and we thank them for their services
over this time. Grant Thornton has confirmed to the Company
that there are no matters connected with their ceasing to hold
office that need to be brought to the attention of the members or
creditors of the Company for the purposes of section 519 of the
Companies Act 2006.
For
further information contact:
RUA
Life
Sciences
Tel: +44 (0)1294 317073
Bill Brown, Chairman
Lachlan Smith, Chief Financial
Officer
Cavendish Capital Markets Limited (Nominated Adviser and
Broker) Tel: +44 (0)20 7220
0500
Giles Balleny / Dan Hodkinson
(Corporate Finance)
Dale Bellis / Charlie Combe (Sales
& ECM)
Michael Johnson
(Sales)
About RUA Life Sciences
The RUA Life
Sciences group was created in April
2020 when RUA Life Sciences Plc (formerly known
as AorTech International Plc) acquired RUA Medical
Devices Limited to create a fully formed medical device
business. RUA Life Sciences is the holding company of the
Group's four trading businesses, each exploiting the Group's
patented polymer technology.
Our vision is to improve the lives
of millions of patients by enabling medical devices with
Elast-EonTM, the world's leading long-term implantable polyurethane.
Whether it is licensing Elast-EonTM, manufacturing a device or
component, or developing next generation medical devices,
a RUA Life Sciences business is pursuing our
vision.
Elast-Eon™'s biostability is
comparable to silicone while exhibiting excellent mechanical, blood
contacting and flex-fatigue properties. These polymers can be
processed using conventional thermoplastic extrusion and moulding
techniques. With over 8 million implants and 15 years of successful
clinical use, RUA's polymers are proven in long-term life enabling
applications.
The Group's four business units
are:
|
RUA
Contract Manufacture:
|
End-to-end contract developer and
manufacturer of medical devices and implantable fabric
specialist.
|
|
RUA
Biomaterials:
|
Licensor of
Elast-EonTM polymers to the medical device industry.
|
|
RUA
Vascular:
|
Commercialisation of open surgical
vascular grafts and patches
|
|
RUA
Structural Heart:
|
Development of polymeric leaflet
systems for heart valves.
|